Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLIN YANG
About this trial
For patients with metastatic gastric cancer, the efficacy of current standard treatments outlined in the guidelines is far from meeting the clinical demand. This study aims to explore the efficacy and safety of trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab as a novel third-line or later-line therapy for metastatic gastric cancer patients.
Eligibility criteria
Qualifiers
Patients with histopathological confirmed gastric/GEJ adenocarcinoma.
The clinical stage was IV, according to AJCC 8th edition.
Patients had received at least two systematic therapies.
Patients had received or not received immunotherapy.
Disqualifiers
Histopathological types other than adenocarcinoma include squamous cell carcinoma, adenosquamous carcinoma, neuroendocrine carcinoma, etc.
Known hypersensitivity or previous treatment with trifluridine/tipiracil or any of its components or excipients.
Known hypersensitivity to any component or excipients of bevacizumab.
Requirement for systemic corticosteroids (>10mg/day of prednisone or equivalent other corticosteroids, for a continuous treatment of ≥7 days) or immunosuppressive therapy within 14 days before enrollment; excluding inhaled or topical steroid use, or hormone therapy for adrenal insufficiency at physiological replacement doses; short-term (≤7 days) corticosteroids are allowed for prevention (e.g., contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity caused by contact allergens).
Trial design
Treatments tested in this trial
- trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab
Treatment groups
31 Participants
are divided into 1 treatment groupSponsors and collaborators
LIN YANG
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor institution
Source ClinicalTrials.gov